WINTON GROUP Ltd Purchases 33,613 Shares of The Cooper Companies, Inc. $COO

WINTON GROUP Ltd lifted its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 379.0% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 42,483 shares of the medical device company’s stock after buying an additional 33,613 shares during the quarter. WINTON GROUP Ltd’s holdings in Cooper Companies were worth $3,046,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Avalon Trust Co purchased a new stake in shares of Cooper Companies during the second quarter worth about $25,000. Root Financial Partners LLC boosted its stake in Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after purchasing an additional 162 shares during the period. SJS Investment Consulting Inc. boosted its stake in Cooper Companies by 107.5% in the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after purchasing an additional 187 shares during the period. Elevation Wealth Partners LLC raised its position in shares of Cooper Companies by 1,136.4% during the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after buying an additional 375 shares during the last quarter. Finally, Continuum Advisory LLC purchased a new position in shares of Cooper Companies in the second quarter worth $30,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Analyst Ratings Changes

COO has been the subject of several research analyst reports. The Goldman Sachs Group set a $61.00 target price on shares of Cooper Companies in a research note on Wednesday, May 27th. Bank of America reaffirmed a “neutral” rating and issued a $65.00 target price (down from $80.00) on shares of Cooper Companies in a report on Thursday. Piper Sandler lowered Cooper Companies from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $86.00 to $59.00 in a research note on Thursday. KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. Finally, Robert W. Baird set a $61.00 price objective on Cooper Companies and gave the stock a “neutral” rating in a report on Thursday. Five research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cooper Companies currently has an average rating of “Hold” and a consensus price target of $71.47.

Cooper Companies Trading Down 0.5%

COO opened at $53.91 on Friday. The firm has a market cap of $10.51 billion, a P/E ratio of 18.40, a P/E/G ratio of 1.45 and a beta of 0.82. The Cooper Companies, Inc. has a 12 month low of $51.01 and a 12 month high of $89.83. The company has a current ratio of 1.22, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23. The stock has a 50-day moving average of $71.62 and a 200 day moving average of $69.70.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, research analysts forecast that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies announced that its Board of Directors has authorized a stock buyback plan on Wednesday, September 9th that permits the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization permits the medical device company to buy up to 22.7% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
• Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
• Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
• Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
• Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
• Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

Cooper Companies Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.